Hughes Hubbard, S&C Advise on Merck's Idenix Buy

Moving to expand its product offerings aimed at treating hepatitis C, pharmaceutical giant Merck & Co. announced Monday that it has agreed to buy Cambridge, Ma.-based Idenix Pharmaceuticals Inc. for $3.85 billion.

YOUR COMPLIMENTARY 15-DAY LAW.COM TRIAL HAS ENDED.
Subscribe now to continue reading →

To continue reading, upgrade and become a Law.com subscriber.
Get 2 MONTHS FREE when you sign up for a 12 month subscription.